These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25326386)

  • 1. The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae.
    Madeo M; Kovács AD; Pearce DA
    J Biol Chem; 2014 Nov; 289(48):33066-71. PubMed ID: 25326386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator.
    Stahl SM
    J Clin Psychiatry; 2004 Sep; 65(9):1162-3. PubMed ID: 15367040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.
    Nowack A; Malarkey EB; Yao J; Bleckert A; Hill J; Bajjalieh SM
    PLoS One; 2011; 6(12):e29560. PubMed ID: 22220214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
    Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F
    Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis.
    Lee J; Daniels V; Sands ZA; Lebon F; Shi J; Biggin PC
    PLoS One; 2015; 10(2):e0116589. PubMed ID: 25692762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.
    Stockburger C; Miano D; Baeumlisberger M; Pallas T; Arrey TN; Karas M; Friedland K; Müller WE
    J Alzheimers Dis; 2016; 50(1):201-15. PubMed ID: 26639968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visualization of SV2A conformations in situ by the use of Protein Tomography.
    Lynch BA; Matagne A; Brännström A; von Euler A; Jansson M; Hauzenberger E; Söderhäll JA
    Biochem Biophys Res Commun; 2008 Oct; 375(4):491-5. PubMed ID: 18692481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
    Serajee FJ; Huq AM
    Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA
    Wood M; Daniels V; Provins L; Wolff C; Kaminski RM; Gillard M
    J Pharmacol Exp Ther; 2020 Jan; 372(1):1-10. PubMed ID: 31619465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of mammalian GLUT glucose transporters in a heterologous yeast expression system.
    Wieczorke R; Dlugai S; Krampe S; Boles E
    Cell Physiol Biochem; 2003; 13(3):123-34. PubMed ID: 12876383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
    Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y
    Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
    Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
    J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.